



**Press Release, 25 October 2010**

## **Nomination Committee appointed for 2010-2011**

Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, today announces that a new Nomination Committee has been appointed consisting of; Maria Wikström, Länsförsäkringar Fondförvaltning AB, Bo Öberg, representing A shareholders, Frank Larsson, Handelsbanken Kapitalförvaltning and Göran Pettersson, Chairman of the Board.

Pursuant to an AGM resolution, the Nomination Committee shall consist of the Chairman of the Board and three shareholder representatives, for which the three largest shareholders as of the end of the third quarter 2010 shall first be invited.

### **For additional information, please contact;**

Rein Piir, CFO & VP Investor Relations; cell phone +46 708 537 292.

### **About Medivir**

Medivir is a research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product Xerese™/Xerclear®. Medivir's key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

Xerese™/Xerclear® is an innovative treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and with Meda in North America. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

**For more information on Medivir, please see the company website: [www.medivir.se](http://www.medivir.se)**